Almirall Received EC’s Approval for Ebglyss (lebrikizumab) to Treat Moderate-to-severe Atopic Dermatitis
Shots:
- The approval was based on 3 P-III clinical trials incl. (ADvocate 1) & (ADvocate 2) evaluating lebrikizumab as monotx. & (Adhere) evaluating lebrikizumab + TCS in adult & adolescent patients (n=1300) with moderate-to-severe atopic dermatitis
- The results showed that disease extent & severity reduced by 75% (EASI-75) in 6/10 & 7/10 patients receiving monotx. & combination therapy at 16wks. & ~80% of the 16wks. responder depicted sustained skin clearance, itch relief & reduced disease severity
- Almirall has the license to develop & commercialize lebrikizumab for dermatology indications incl. AD in Europe whereas Eli Lilly holds the exclusive development & commercialization rights for lebrikizumab in the US & ROW
Ref: Almirall | Image: Almirall
Related News:- EpimAb Biotherapeutics Entered into a License Agreement with Almirall to Develop Bispecific Antibody
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Tags
Kritika is a content writer at PharmaShots. She is interested in covering recent innovations from the pharma & MedTech industry. She covers news related to Product approvals, clinical trial results, and updates. She can be contacted at connect@pharmashots.com.
